Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

74.00 -0.19 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,214,727
Open 74.51
Bid (Size) 73.60 (3)
Ask (Size) 74.33 (1)
Prev. Close 74.19
Today's Range 73.95 - 75.32
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Four Stocks To Watch This Week - Monday, August 5
The unease we've been mentioning over the past several weeks has borne bearish fruit in the last two weeks. The good news is that stocks are correcting across the board, which means they will... 
Via Talk Markets

Performance

YTD
-11.10%
-11.10%
1 Month
+9.55%
+9.55%
3 Month
+13.05%
+13.05%
6 Month
-4.79%
-4.79%
1 Year
-8.27%
-8.27%

More News

Read More
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Via The Motley Fool
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
Via InvestorPlace
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
This Is What Whales Are Betting On Gilead Sciences
Via Benzinga
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
Via Benzinga
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Via Benzinga
Check Out What Whales Are Doing With GILD
Via Benzinga
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Via The Motley Fool
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Via Benzinga
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Via Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
Via Talk Markets
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
Via The Motley Fool
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.